{"id":1075,"date":"2020-10-01T05:07:28","date_gmt":"2020-10-01T05:07:28","guid":{"rendered":"http:\/\/axxessbeauty.com\/wordpress1\/?p=1075"},"modified":"2021-03-23T08:02:35","modified_gmt":"2021-03-23T08:02:35","slug":"axxessbio-and-dipharma-provide-solutions-for-metabolic-diseases","status":"publish","type":"post","link":"https:\/\/www.axxessbio.com\/?p=1075","title":{"rendered":"AxxessBio and Dipharma provide solutions for metabolic diseases"},"content":{"rendered":"\n<p>October 2020, an exclusive agreement has been signed between AxxessBio and Dipharma&nbsp; SA for Sapropterin and Miglustat in selected countries in Asia. Sapropterin and Miglustat are medicines for rare&nbsp;metabolic&nbsp;diseases. Sapropterin is indicated for Phenylketonuria and BH4 Deficiency. Miglustat is indicated for Type 1 Gaucher Disease and Niemann-Pick C Disease.<\/p>&nbsp;\n\n\n\n<p>Metabolic&nbsp;diseases&nbsp;consist of disorders that disrupt normal metabolism, are progressive and lead to disabilities or even death when left untreated. They are usually inherited and rare. A rare disease is defined as a disease that affects a small percentage of the population (5 in 10,000 in Europe and less than 200,000 in the US).<\/p>&nbsp;\n\n\n\n<p>Dipharma&nbsp;SA is a young company based in Chiasso, Switzerland. It is pioneering an agile pharmaceutical business model by&nbsp;discovering how to turn the slow and complex process of making drugs for rare&nbsp;metabolic&nbsp;diseases, into a rapid and agile process to deliver high quality drugs at fair price.<\/p>&nbsp;\n\n\n\n<p>For more information on&nbsp;Dipharma&nbsp;and its products, please visit&nbsp;<a href=\"http:\/\/www.dipharma.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.dipharma.ch<\/a><\/p>&nbsp;\n","protected":false},"excerpt":{"rendered":"<p>October 2020, an exclusive agreement has been signed between AxxessBio and Dipharma&nbsp; SA for Sapropterin and Miglustat in selected countries in Asia. Sapropterin and Miglustat are medicines for rare&nbsp;metabolic&nbsp;diseases. Sapropterin is indicated for Phenylketonuria and BH4 Deficiency. Miglustat is indicated for Type 1 Gaucher Disease and Niemann-Pick C Disease. &nbsp; Metabolic&nbsp;diseases&nbsp;consist of disorders that disrupt [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":158,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=\/wp\/v2\/posts\/1075"}],"collection":[{"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1075"}],"version-history":[{"count":1,"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=\/wp\/v2\/posts\/1075\/revisions"}],"predecessor-version":[{"id":1896,"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=\/wp\/v2\/posts\/1075\/revisions\/1896"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=\/wp\/v2\/media\/158"}],"wp:attachment":[{"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.axxessbio.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}